Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Brümmendorf TH, Leip E, Viqueira A, Gambacorti-Passerini C. Cortes JE, et al. Haematologica. 2023 Dec 1;108(12):3454-3459. doi: 10.3324/haematol.2022.281944. Haematologica. 2023. PMID: 37439348 Free PMC article. Clinical Trial. No abstract available.
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Budde LE, et al. Nat Med. 2024 Jan;30(1):229-239. doi: 10.1038/s41591-023-02726-5. Epub 2023 Dec 10. Nat Med. 2024. PMID: 38072960 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112195
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, Hicks LK, Hay AE, Assouline S, Fraser G, Balitsky A, Mangel J, Owen C, Reiman A, Sehn L, Sutherland H, Zhang T, Arnold C, Leite T, McCarthy E, Cooper C, Langlois MA, Arianne Buchan C; VIP Study Investigators. Bhella S, et al. Vaccine. 2024 Oct 24;42(24):126074. doi: 10.1016/j.vaccine.2024.06.041. Epub 2024 Jun 28. Vaccine. 2024. PMID: 38944577 Free article.
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
Trotman J, Zinzani PL, Song Y, Delarue R, Kim P, Ivanova E, Korde R, Mayer J, De Oliveira AC, Assouline SE, Flowers CR, Barnes G. Trotman J, et al. Among authors: assouline se. Curr Med Res Opin. 2024 Nov;40(11):1863-1871. doi: 10.1080/03007995.2024.2409837. Epub 2024 Oct 14. Curr Med Res Opin. 2024. PMID: 39376156 Clinical Trial.
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment.
Benoit A, Abraham MJ, Li S, Kim J, Estrada-Tejedor R, Bakadlag R, Subramaniam N, Makhani K, Guilbert C, Tu R, Salaciak M, Klein KO, Coyle KM, Hilton LK, Santiago R, Dmitrienko S, Assouline S, Morin RD, Del Rincon SV, Johnson NA, Mann KK. Benoit A, et al. Int J Hematol. 2024 Mar;119(3):275-290. doi: 10.1007/s12185-023-03692-x. Epub 2024 Jan 29. Int J Hematol. 2024. PMID: 38285120 Free PMC article.
32 results